Current status of sensitivity to praziquantel in a focus of potential drug resistance in Egypt

Efficacy and side effects of praziquantel in the treatment of Schistosomiasis mansoni in schoolchildren in Shesha Kekele Elementary School, Wondo Genet, Southern Ethiopia

“…The most frequent of these were headache, nausea, and abdominal pain. These observations were in agreement with previous studies in Ethiopia and other countries [21,29,31,37,44] . Nevertheless, there are variations in the overall prevalence and frequency of the different symptoms observed.…”

“…Also, high percent of S. mansoni infection (74.9%) in general and heavy infection cases (42.4%, 95/224) in particular before treatment in our study population might have decreased the cure rate of the drug. Unlike the present study, previous studies which documented higher efficacy (>85%) for PZQ were conducted in areas of lower S. mansoni prevalence (<51%) and light intensity infection [30][31][32] .…”

“…Unlike a single administration in the present study, most of the previous studies that have reported high efficacy of PZQ administered two or three treatments spaced at certain time intervals [16,21,31,37,38] . In areas with heavy transmission of schistosomiasis, it has been suggested that people might have been infected in the previous 3-5 weeks.…”

“…These values are in general within the usual cure rate ranges (63-95%) of PZQ against S. mansoni reported in different epidemiological settings [4,[26][27][28] . Some previous studies have reported efficacy higher than 85% for PZQ [29][30][31][32][33][34] , while others have reported lower (<63%) efficacy for the drug [13][14][15][16][17][18][19][20][21]35,36] . Such variations might be attributable to differences in the number of treatment, factors related to the host, parasite, and drugs or to the methodology.…”

Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs

“…Independent evaluations of myrrh in experimental animals ) and humans (Barakat, Elmorshedy and Fenwick, 2005 ;Botros et al 2005 c) have however found very little evidence for such activity and this product should therefore be removed from the market for schistosomicides.…”